• Newsletter
  • Search
  • Contacto
  • Home (next newsletter)
  • Home
  • News # 80 | Jun. 2018
  • News # 81 | Jul. 2018
  • News # 82 | Set. 2018
  • News # 83 | Oct. 2018
  • News # 84 | Nov. 2018
  • News # 85 | Dec. 2018
  • News # 86 | Jan. 2019
  • News # 87 | Feb. 2019
  • News # 88 | Mar. 2019
  • News # 89 | Apr. 2019
  • News # 90 | May. 2019
  • News # 91 | Jun. 2019
  • News # 92 | Jul. 2019
  • News # 93 | sep. 2019
  • Newsletters
    • 2008 – 2009
      • News # 1 | nov. 2008
      • News # 10 | nov/dez. 2009
      • News # 2 | dec. 2008
      • News # 3 | jan/fev. 2009
      • News # 4 | mar. 2009
      • News # 5 | abr. 2009
      • News # 6 | mai/jun. 2009
      • News # 7 | jul. 2009
      • News # 8 | ago/set. 2009
      • News # 9 | out. 2009
    • 2010 – 2011
      • News # 11 | jan/fev. 2010
      • News # 12 | mar. 2010
      • News # 13 | abr. 2010
      • News # 14 | mai. 2010
      • News # 15 | jun/jul. 2010
      • News # 16 | ago/set. 2010
      • News # 17 | out/nov. 2010
      • News # 18 | dez. 2010
      • News # 19 | jan/fev. 2011
      • News # 20 | mar/abr. 2011
      • News # 21 | mai/jun. 2011
      • News # 22 | jul/ago. 2011
      • News # 23 | set/out. 2011
      • News # 24 | nov/dez. 2011
    • 2012 – 2013
      • News # 25 | jan. 2012
      • News # 26 | fev/mar. 2012
      • News # 27 | jun. 2012
      • News # 28 | ago. 2012
      • News # 29 | set/out. 2012
      • News # 30 | nov/dez. 2012
      • News # 31 | jan. 2013
      • News # 32 | mar. 2013
      • News # 33 | abr. 2013
      • News # 34 | mai. 2013
      • News # 35 | jun. 2013
      • News # 36 | set. 2013
      •  News # 37 | out. 2013
      • News # 38 | nov/dez. 2013
    • 2014 – 2015
      • News # 39 | jan/fev. 2014
      • News # 40 | mar. 2014
      • News # 41 | abr/mai. 2014
      • News # 42 | jun/jul. 2014
      • News # 43 | set. 2014
      • News # 44 | out/nov. 2014
      • News # 45 | dez. 2014
      • News # 46 | jan. 2015
      • News # 47 | fev. 2015
      • News # 48 | abr. 2015
      • News # 49 | mai. 2015
      • News # 50 | jun. 2015
      • News # 51 | set. 2015
      • News # 52 | out. 2015
      • News # 53 | dez. 2015
    • 2016 – 2017
      • News # 54 | jan. 2016
      • News # 55 | fev. 2016
      • News # 56 | mar. 2016
      • News # 57 | abr. 2016
      • News nº 58 | may 2016
      • News # 59 | jun. 2016
      • News # 60 | jul. 2016
      • News # 61 | set. 2016
      • News # 62 | out. 2016
      • News # 63 | nov/dez. 2016
      • News # 64 | jan. 2017
      • News # 65 | fev. 2017
      • News # 66 | mar. 2017
      • News # 67 | apr. 2017
      • News # 68 | may 2017
      • News # 69 | jun. 2017
      • News # 70 | jul. 2017
      • News # 71 | set. 2017
      • News # 72 | out. 2017
      • News # 73 | nov. 2017
      • News # 74 | dez. 2017
    • 2018
      • News # 75 | jan. 2018
      • News # 76 | fev. 2018
      • News # 77 | mar. 2018
      • News # 78 | abr. 2018
      • News #79 | May 2018
  • Subscribe Newsletter
My Company
  • Home
  • Newsletters
    • 2018 – 2019
      • News nº 92 | jul. 2019
      • News nº 91 | jun. 2019
      • News nº 90 | Mai. 2019
      • News nº 89 | Abr. 2019
      • News nº 88 | Mar. 2019
      • News nº 87 | Fev. 2019
      • News nº 86 | Jan. 2019
      • News nº 85 | Dez. 2018
      • News nº 84 | Nov. 2018
      • News nº 83 | Out. 2018
      • News nº 82 | Set. 2018
      • News nº 81 | Jul. 2018
      • News nº 80 | Jun. 2018
      • News Nº 79 | Mai. 2018
      • News nº 78 | abr. 2018
      • News nº 77 | mar. 2018
      • News nº 76 | fev. 2018
      • News nº 75 | jan. 2018
    • 2016 – 2017
      • News nº 74 | dez. 2017
      • News # 73 | nov. 2017
      • News # 72 | out. 2017
      • News # 70 | set. 2017
      • News nº 70 | jul. 2017
      • News nº 69 | jun. 2017
      • News nº 68 | mai. 2017
      • News nº 67 | abr. 2017
      • News nº 66 | mar. 2017
      • News nº 65 | fev. 2017
      • News nº 64 | jan. 2017
      • News nº 63 | nov/dez. 2016
      • News nº 62 | out. 2016
      • News nº 61 | set. 2016
      • News nº 60 | jul. 2016
      • News nº 59 | jun. 2016
      • News nº 58 | mai. 2016
      • News nº 57 | abr. 2016
      • News nº 56 | mar. 2016
      • News nº 55 | fev. 2016
      • News nº 54 | jan. 2016
    • 2014 – 2015
      • News nº 53 | dez. 2015
      • News nº 52 | out. 2015
      • News nº 51 | set. 2015
      • News nº 50 | jun. 2015
      • News nº 49 | mai. 2015
      • News nº 48 | abr. 2015
      • News nº 47 | fev. 2015
      • News nº 46 | jan. 2015
      • News nº 45 | dez. 2014
      • News nº 44 | out/nov. 2014
      • News nº 43 | set. 2014
      • News nº 42 | jun/jul. 2014
      • News nº 41 | abr/mai. 2014
      • News nº 40 | mar. 2014
      • News nº 39 | jan/fev. 2014
    • 2012 – 2013
      • News nº 38 | nov/dez. 2013
      • News nº 37 | out. 2013
      • News nº 36 | set. 2013
      • News nº 35 | jun. 2013
      • News nº 34 | mai. 2013
      • News nº 33 | abr. 2013
      • News nº 32 | mar. 2013
      • News nº 31 | jan. 2013
      • News nº 30 | nov/dez. 2012
      • News nº 29 | set/out. 2012
      • News nº 28 | ago. 2012
      • News nº 27 | jun. 2012
      • News nº 26 | fev/mar. 2012
      • News nº 25 | jan. 2012
    • 2010 – 2011
      • News nº 24 | nov/dez. 2011
      • News nº 23 | set/out. 2011
      • News nº 22 | jul/ago. 2011
      • News nº 21 | mai/jun. 2011
      • News nº 20 | mar/abr. 2011
      • News nº 19 | jan/fev. 2011
      • News nº 18 | dez. 2010
      • News nº 17 | out/nov. 2010
      • News nº 16 | ago/set. 2010
      • News nº 15 | jun/jul. 2010
      • News nº 14 | mai. 2010
      • News nº 13 | abr. 2010
      • News nº 12 | mar. 2010
      • News nº 11 | jan/fev. 2010
    • 2008 – 2009
      • News nº 10 | nov/dez. 2009
      • News nº 9 | out. 2009
      • News nº 8 | ago/set. 2009
      • News nº 7 | jul. 2009
      • News nº 6 | mai/jun. 2009
      • News nº 5 | abr. 2009
      • News nº 4 | mar. 2009
      • News nº 3 | jan/fev. 2009
      • News nº 2 | dez. 2008
      • News nº 1 | nov. 2008
  • Subscrever Newsletter
  • Contacto
Main Menu
  • Home
  • Newsletters
    • 2018 – 2019
      • News nº 92 | jul. 2019
      • News nº 91 | jun. 2019
      • News nº 90 | Mai. 2019
      • News nº 89 | Abr. 2019
      • News nº 88 | Mar. 2019
      • News nº 87 | Fev. 2019
      • News nº 86 | Jan. 2019
      • News nº 85 | Dez. 2018
      • News nº 84 | Nov. 2018
      • News nº 83 | Out. 2018
      • News nº 82 | Set. 2018
      • News nº 81 | Jul. 2018
      • News nº 80 | Jun. 2018
      • News Nº 79 | Mai. 2018
      • News nº 78 | abr. 2018
      • News nº 77 | mar. 2018
      • News nº 76 | fev. 2018
      • News nº 75 | jan. 2018
    • 2016 – 2017
      • News nº 74 | dez. 2017
      • News # 73 | nov. 2017
      • News # 72 | out. 2017
      • News # 70 | set. 2017
      • News nº 70 | jul. 2017
      • News nº 69 | jun. 2017
      • News nº 68 | mai. 2017
      • News nº 67 | abr. 2017
      • News nº 66 | mar. 2017
      • News nº 65 | fev. 2017
      • News nº 64 | jan. 2017
      • News nº 63 | nov/dez. 2016
      • News nº 62 | out. 2016
      • News nº 61 | set. 2016
      • News nº 60 | jul. 2016
      • News nº 59 | jun. 2016
      • News nº 58 | mai. 2016
      • News nº 57 | abr. 2016
      • News nº 56 | mar. 2016
      • News nº 55 | fev. 2016
      • News nº 54 | jan. 2016
    • 2014 – 2015
      • News nº 53 | dez. 2015
      • News nº 52 | out. 2015
      • News nº 51 | set. 2015
      • News nº 50 | jun. 2015
      • News nº 49 | mai. 2015
      • News nº 48 | abr. 2015
      • News nº 47 | fev. 2015
      • News nº 46 | jan. 2015
      • News nº 45 | dez. 2014
      • News nº 44 | out/nov. 2014
      • News nº 43 | set. 2014
      • News nº 42 | jun/jul. 2014
      • News nº 41 | abr/mai. 2014
      • News nº 40 | mar. 2014
      • News nº 39 | jan/fev. 2014
    • 2012 – 2013
      • News nº 38 | nov/dez. 2013
      • News nº 37 | out. 2013
      • News nº 36 | set. 2013
      • News nº 35 | jun. 2013
      • News nº 34 | mai. 2013
      • News nº 33 | abr. 2013
      • News nº 32 | mar. 2013
      • News nº 31 | jan. 2013
      • News nº 30 | nov/dez. 2012
      • News nº 29 | set/out. 2012
      • News nº 28 | ago. 2012
      • News nº 27 | jun. 2012
      • News nº 26 | fev/mar. 2012
      • News nº 25 | jan. 2012
    • 2010 – 2011
      • News nº 24 | nov/dez. 2011
      • News nº 23 | set/out. 2011
      • News nº 22 | jul/ago. 2011
      • News nº 21 | mai/jun. 2011
      • News nº 20 | mar/abr. 2011
      • News nº 19 | jan/fev. 2011
      • News nº 18 | dez. 2010
      • News nº 17 | out/nov. 2010
      • News nº 16 | ago/set. 2010
      • News nº 15 | jun/jul. 2010
      • News nº 14 | mai. 2010
      • News nº 13 | abr. 2010
      • News nº 12 | mar. 2010
      • News nº 11 | jan/fev. 2010
    • 2008 – 2009
      • News nº 10 | nov/dez. 2009
      • News nº 9 | out. 2009
      • News nº 8 | ago/set. 2009
      • News nº 7 | jul. 2009
      • News nº 6 | mai/jun. 2009
      • News nº 5 | abr. 2009
      • News nº 4 | mar. 2009
      • News nº 3 | jan/fev. 2009
      • News nº 2 | dez. 2008
      • News nº 1 | nov. 2008
  • Subscrever Newsletter
  • Contacto

Vera Mendonça – on radiotherapy for breast cancer

By Joana Ferreira de Sousa On 30 October, 2018 2018 | Did you know? Comments Off on Vera Mendonça – on radiotherapy for breast cancer No tags

With an empathetic face, she leaves an office in one of the corridors of the Santa Maria Hospital that nobody wants to cross – the Radiotherapy corridor.
She’s as reserved as she’s gentle. Vera Mendonça is now a specialist in Radiotherapy and says she’s a “daughter of this house;” she studied at the Faculty of Medicine of the University of Lisbon and she stayed at the Santa Maria Hospital were she specialised. While she was an intern and a new mother of twins – the first 2 out of a total of 6 children -, she chose Pneumology in her second year of general internship, but her experience in internal emergency room soon showed that it was not the right choice for her. It was a conversation with two of her best friends that aroused her curiosity to learn more about Radiotherapy. A department that didn’t have a central emergency room, was very innovative from the technological point of view, and offered more stable schedules for someone who was also a mother, was the choice she deems to have been the right one.
That’s when she met her tutor, Marília Jorge, who had always worked with breast cancer and Gynaecology; she wanted to stay with her in Pathology and that’s where she’s spent the last 8 years.
She’s at the emergency room one day a week, from 8 a.m. to 9 p.m.; there they receive patients from the hospital and referral areas and deal mainly with 3 clinical situations: the vena cava syndrome (obstruction of blood flow through the superior vena cava), bleeding (which stops with radiotherapy), and spinal cord compression (lesions and illnesses that put pressure on the spinal cord). Her role is to decide what dose of radiation to administer starting at 24-48h, single dose or divided into several days (with a smaller dose per fraction).
What brought us together to talk was the issue of breast cancer and what happens to a woman who undergoes radiotherapy. We were looking for simple questions for those who are faced with bad news for the first time and we realised that when we open doors with answers, everything seems to become less dark.

Please demystify radiotherapy for us.
Vera Mendonça: It’s one of the therapeutic modalities used to treat cancer. About 50% of cancer diseases are currently treated with radiotherapy. This treatment is associated with surgery, used as a single therapy, or associated with surgery and chemotherapy.

And how is radiotherapy applied?
Vera Mendonça: It’s applied using a machine known as linear accelerator; one of the great technological advances was the replacement of the cobalt pump by the linear accelerator, and it was from that point on, in the mid-1990s, that it was possible to do 3D radiotherapy; that’s because treatments are now being planned by CAT (in some Centres they are planned by RMI or PET – Positron-emission tomography, a nuclear medical imaging technique that uses molecules which include a radioactive component). The advancement in imaging techniques has also improved treatment planning, and that is a great advantage because we are able to irradiate our target organ more effectively and evaluate the doses of radiation that reach the organs at risk precisely because we design them individually.

When we do a treatment with radiations we are killing bad cells, of course, but we are also hitting healthy cells. In this difficult balance, is it still better to kill bad cells, even if you’re hitting good cells?
Vera Mendonça: Yes, of course; partly because the radiobiology of radiation treatments allows it, “healthy cells” are able to recover because radiation acts in a phase of the cell cycle in which malignant cells cannot recover from the damage that is done to their DNA, but benign cells can. And that’s why treatments are fractionated and we don’t give the full dose of radiation in a single day (with a few exceptions); we divide the radiation into several daily fractions, so cells can recover in the meantime. It’s 5 days of treatment, 2 days of rest. This break is very important to recover from damage.

We know there is collateral damage to the cells, but that’s on the inside. And on the outside, what happens to a patient subject to radiotherapy?
Vera Mendonça: They feel more tired, and that happens in general to patients who receive radiation. From the pathophysiological point of view there’s no specific reason for that. Maybe the fact that they come and go every day is exhausting, as these are curative treatments. The total dose is divided into small daily fractions, but they must come every working day. Currently we have more condensed breast treatment schemes that are equally effective in terms of local control and cosmetic outcome, and so instead of offering patients 5- or 6-week-long treatments, we are offering 3- to 4-week-long treatments, which means that we’re slightly increasing the dose per fraction. This has all been studied and confirmed, of course. But it’s important to note that even these women who undergo 3-week-long treatments mention fatigue. On the other hand, when it comes to toxicity, and according to the area we are dealing with, it’s a problem that emerges as the weeks go by; in the case of the breast, the skin will become progressively redder and wounds may appear. The degree of toxicity depends on the type of skin, hydration, adherence to the requested care, previous therapies, co-morbidities. These are ways to minimise cutaneous toxicity, which is the only one that the patient can see. We can’t see pulmonary or cardiac toxicity; we only detect it and diagnose it when there are complaints.

But if there are no obvious complaints, they will not undertake medical examinations to screen for collateral lesions, is that it?
Vera Mendonça: Yes, if there are no complaints we don’t conduct further tests to assess the surrounding toxicity. With regard to chronic cardiac toxicity, several international recommendations are being developed for the follow-up of patients irradiated for left-sided breast cancer.

Do patients stick to the recommendations they are given?
Vera Mendonça: In most cases; in the summer it’s a bit more difficult.

In the summer? Why?
Vera Mendonça: It has to do with clothes, because it’s not advisable to wear a bra directly on skin that is being irradiated on a daily basis. You should always wear a cotton sweater under your bra to minimise the risk of wound; elastics, lace, all of these can increase the risk of wound. With warmth patients feel more reluctant to adhere to this recommendation and therefore we see more grade-2 toxicity, perhaps because they’re less careful. In the winter we see mostly grade-1 toxicity, which is the same as an erythema, oedema, or pruritus on the breast.

Can you trace the profile of a woman with breast cancer?
Vera Mendonça: That’s an interesting question because this is an issued we discuss with oncologists. Of course there are exceptions, but I think that all cancer patients have a certain psychological profile; breast cancer patients also have a profile, and they are usually more anxious, some more depressed, generally more stressed women. Please note that this is not a label, and it doesn’t rely on any established evidence, but rather our perception of the sample we treat annually.

Can this speed up the disease process?
Vera Mendonça: In women who have experienced traumatic situations and were left with emotional damage, these can affect the disease, because they affect their immune system. On the other hand, each of us has a specific genetic profile, and that makes us more prone to certain diseases. And when all these intrinsic and extrinsic factors come together, “get in tune” and combine themselves, that’s when the disease reveals itself. So, I believe that in some cases the disease may actually be triggered by a life event. All these women often mention this, you know, the fact that they believe they experienced stressful situations at home or at work, which may have been responsible for triggering the disease. And many of them – some who are still very young, they are 30/40 years old and have breast cancer – say “I’ve always been healthy, I don’t smoke, I don’t drink, I even exercise, why did this happen to me?”

And why did it happen to them?
Vera Mendonça: I don’t think anyone can answer that. Because there’s genetic cancer and non-genetic cancer, and most of the cancer is not genetic; the disease happens when all the factors, both extrinsic and intrinsic, come together in the same person. According to literature, it’s a multifactorial question.

If it’s not genetic, is it worth investing in prevention?
Vera Mendonça: Of course, because the earlier we find it, the better the prognosis. There’s a difference in finding a stage-1 tumour or a stage-3 tumour, because that has a great impact on survival.

But, in preventive exams, don’t you receive signs from the body saying “hold on, there might be a disease here?”
Vera Mendonça: No, we don’t. We can’t predict it.

Is breast cancer as aggressive in an 80-year-old woman as in a 40-year-old woman? In other words, do cancer cells slow down as metabolism slows down?
Vera Mendonça: It depends on the biology of the tumour. We’ve had cases of patients over 80 whose breast cancer had an aggressive biological profile. The problem is that, because many of them have several co-morbidities (quantification of various diseases), that forces us to exclude some therapeutic modalities. As treatment we have radiotherapy, surgery and hormone therapy (chemotherapy and immunotherapy are used in selected cases), for women who are hormone-dependent and have a better prognosis; for the triple negative profile we have fewer therapeutic options. We have to adjust the treatment to the patient we have before us.

I know that you’re a doctor and you’re used to dealing with this reality every day, but you’re also a woman. Do you struggle with this disease as a woman, or can you filter this reality and don’t allow these issues to affect you?
Vera Mendonça As time goes by, we manage to stand more and more on the side, but at the same time we have a different bond with the patient. I’m able to see past the disease but, at the same time, I try walking in the patient’s shoes. I try to understand what she’s feeling and establish an emotional relationship. To get more of them, we also have to give them more. Breast cancer patients need to be emotionally touched in order to better correspond to what we ask of them next. Radiation frightens them, but when their doubts have been cleared, they are calmer and less afraid of toxicity.

Is there still room for advancements in radiotherapy?
Vera Mendonça: Of course, imaging techniques are constantly evolving and each time they do we can offer more possibilities to the patients. Planning associated with the technological evolution of the treatment has been amazing.

********************************
After all, walking across the corridors of a Hospital as huge as Santa Maria may not be as terrifying as we’d imagined, as if we were terrified children in the dark, facing the unknown.
Trusting in the physician we have before us and in therapeutic and technological progress may be the second most important tool to overcome a disease such as breast cancer.
Because the first of all is the inner confidence that every woman must grasp and never want to give up.
And if, along the rockiest road, you receive the news that you have cancer, when you find a physician like Vera Mendonça you can be sure that the odds are more in your favour.

Share

Search

Índice – News nº 83 | out. 2018
 Simbioses
 I Updated Course in Medical Law | Opening Session
 Professor António Gonçalves Ferreira elected President of the European Association of Stereotactic and Functional Neurosurgery
 Living daily with cancer – the testimony of Sandra Lucas
 Dark-haired Maria
 Professor Jorge Draper Mineiro – tribute on the centennial of his birth
 Awards Ceremony of the 5th Annual Health + Solidarity Run
 With a balanced heart!
 Uma aula especial dada pelo Professor Mário Simões
 Beyond Med – A Glance at Medical Education
 Opening of the Master’s Degree in Cardiovascular Rehabilitation
 Ronald Harden is granted the Honoris Causa Doctorate by the University of Lisbon
 Personality Award granted to Fernando Pádua, the “Heart Doctor”.
 The hug between iMM and Laço – a conversation with consultant Lynne Archibald
 Open Access International Week 2018 | National and International Policies
 The Mentoring Project and its novelties
 Carmo Fonseca and the Laboratory that wants to wait for cancer before it appears
 Miguel Castanho to lead project selected for funding by the European Innovation Council
 Find the Researcher you are looking for – Now
 Publicações Científicas (FMUL/HSM/IMM) setembro – outubro 2018
 AIDFM CETERA – Ensaio Clínicos
 Anti-measles medicines – a research led by Miguel Castanho
 ERC 2018 Synergy Grants para Edgar Gomes (iMM)
 Sérgio de Almeida and his new weapon in the fight against breast cancer
 Notícias do Pedagógico
 Vera Mendonça – on radiotherapy for breast cancer
 The ancient book of CDI-Library of FMUL: a legacy that honours the past and helps us build the future
 Lecture “Mediterranean Diet: Health Promoter”
 Dia da Investigação | 12 DEZ – Save the date
 XVII Hospital dos Pequeninos
 II Congresso de Investigação em Medicina das Escolas Médicas Portuguesas | 9 e 10 de novembro 2018
 4th Students Meeting of Mind-Brain College
 “Descomplicar a Pesquisa Bibliográfica”
 Deslocado? – Tem o Espaço S
 Já está à venda a Agenda da Pediatria
 José Manuel de Vasconcelos Pequito Cortez Pimentel (1924-2018)
 Dra. Anabela Maria Rebelo Morais (1955–2018)
My Company

100 AnosPropriedade e Edição: Faculdade de Medicina da Universidade de Lisboa NIPC: 502662875  Periodicidade: Mensal  Diretor: Prof. Doutor Fausto J. Pinto Conselho Editorial: Prof. Doutor Fausto J. Pinto, Profª. Doutora Ana Sebastião, Prof. Doutor Mamede de Carvalho, Prof. Doutor António Vaz Carneiro, Prof. Doutor Miguel Castanho, Dr. Luís Pereira  Equipa Editorial:  Ana Raquel Moreira, Cristina Bastos, Isabel Varela, Joana Sousa, Maria de Lurdes Barata, Rui Gomes, Sónia Teixeira  Colaboração:  Gabinete de Relações Públicas, Internacionais e Comunicação  Versão Inglesa: AP|PORTUGAL- Language Services  Conceção: Metatexto, Lda. e-mail: news@medicina.ulisboa.pt  Sede do Editor e Sede da Redação: Avenida Prof. Egas Moniz, 1649-028 Lisboa Estatuto Editorial Anotado na ERC 

  • Increase Font
  • Decrease Font
  • Black & White
  • Inverse Colors
  • Highlight Links
  • Regular Font
  • Reset
Real Accessability